文献速递MDS 与骨髓增殖性肿瘤

经典骨髓增殖性肿瘤的新兴治疗

Emerging treatments for classical myeloproliferative neoplasms.
PubMed 文献 · Blood · 2016-12-27

综述指出JAK1/JAK2抑制剂芦可替尼改善了骨髓纤维化及伴巨脾和症状负担患者的治疗,并获批用于真性红细胞增多症二线治疗,但现有药物均未显示明确的疾病修饰活性;针对分子异常和细胞通路的新药早期临床试验结果迄今令人失望,毒性有时限制应用。

要点

  • 芦可替尼改善了骨髓纤维化伴巨脾和症状负担患者的治疗,并获批用于真性红细胞增多症二线治疗。
  • 现有药物均未显示明确的疾病修饰活性,干扰素和芦可替尼可使部分患者突变等位基因负荷降低。
  • 针对新靶点药物的早期1期和2期临床试验结果迄今令人失望,毒性有时限制应用。

核心结论

  • 骨髓增殖性肿瘤的治疗格局因芦可替尼发生重大变革,但现有药物对患者主要未满足需求仍大多不足,新药早期试验结果迄今令人失望。

研究设计与样本

  • 综述,基于现行指南、患者风险分层标准和既往经验,批判性阐述骨髓增殖性肿瘤在研新疗法的现状。

主要发现

  • 芦可替尼是JAK1和JAK2抑制剂,用于骨髓纤维化伴巨脾和症状负担患者,并获批作为真性红细胞增多症二线治疗。
  • 部分接受干扰素和芦可替尼治疗的患者显示突变等位基因负荷降低,芦可替尼可能延长较高危骨髓纤维化患者的生存。
  • 对多数新分子虽提供了令人信服的临床前依据,但早期1期和2期临床试验结果迄今令人失望,毒性有时限制应用。

局限性

  • 对多数新分子虽提供了令人信服的临床前依据,但早期1期和2期临床试验结果迄今令人失望。
  • 毒性有时限制新药应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There has been a major revolution in the management of patients with myeloproliferative neoplasms (MPN), and in particular those with myelofibrosis and extensive splenomegaly and symptomatic burden, after the introduction of the JAK1 and JAK2 inhibitor ruxolitinib. The drug also has been approved as second-line therapy for polycythemia vera (PV). However, the therapeutic armamentarium for MPN is still largely inadequate for coping with patients' major unmet needs, which include normalization of life span (myelofibrosis and some patients with PV), reduction of cardiovascular complications (mainly PV and essential thrombocythemia), prevention of hematological progression, and improved quality of life (all MPN). In fact, none of the available drugs has shown clear evidence of disease-modifying activity, even if some patients treated with interferon and ruxolitinib showed reduction of mutated allele burden, and ruxolitinib might extend survival of patients with higher-risk myelofibrosis. Raised awareness of the molecular abnormalities and cellular pathways involved in the pathogenesis of MPN is facilitating the development of clinical trials with novel target drugs, either alone or in combination with ruxolitinib. Although for most of these molecules a convincing preclinical rationale was provided, the results of early phase 1 and 2 clinical trials have been quite disappointing to date, and toxicities sometimes have been limiting. In this review, we critically illustrate the current landscape of novel therapies that are under evaluation for patients with MPN on the basis of current guidelines, patient risk stratification criteria, and previous experience, looking ahead to the chance of a cure for these disorders.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Vannucchi AM, Harrison CN. Emerging treatments for classical myeloproliferative neoplasms. Blood. 2016. PMID: 28028027. doi:10.1182/blood-2016-10-695965

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。